BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,800.00
- Market cap
- ₹1,04,544 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.8×Sector 43.0×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Acquisition Worth ₹29 Cr
Aurobindo's subsidiary Auropharm Overseas will buy 100% of Auro Pharma LLC, a Russian step-down subsidiary, for about Rs 29 crore cash. It is an internal group reorganisation.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Management Change
Aurobindo Pharma's board approved reappointing independent director Mangalam Ramasubramanian Kumar for a second five-year term from April 1, 2027. Shareholder approval by postal ballot is required.
- Execution
- Five years from April 1, 2027
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Aurobindo Pharma Acquisition
Aurobindo Pharma announced a board-approved proposal to merge two wholly owned subsidiaries, Auroactive Pharma into Apitoria Pharma, via NCLT scheme. No cash consideration; the share-exchange ratio issues 23,95,900 shares of Apitoria.
Aurobindo Pharma Dividend
Aurobindo Pharma declared an interim dividend of Rs 7.00 per share for FY27. Record date is 11 November 2026, with payment on or before 20 November.
Aurobindo Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹10,263 Cr (+23.9% YoY), record EBITDA ₹2,156 Cr at 21.0% margin, PAT ₹1,124 Cr (+32.5% YoY). Lannett acquisition completed.
Other annual general meeting announcements
All →Meesho Annual General Meeting
Meesho seeks postal ballot approval, with voting closing 08-Dec-2026, to appoint Sudhir Sitapati as Independent Director. The resolution also covers ₹1 Crore annual remuneration.
Indrayani Biotech Annual General Meeting
Indrayani Biotech's 34th AGM is set for 30 November 2026, with book closure from 24 to 30 November. Remote e-voting runs 27 to 29 November 2026.
Kirloskar Ferrous Industries Annual General Meeting
Kirloskar Ferrous shareholders approved Ajay Shriram Patil's appointment as Director and Joint Managing Director via postal ballot. Both ordinary resolutions passed with over 98% votes in favour.
Gland Pharma Annual General Meeting
Gland Pharma's shareholders approved the appointment of Xingli Wang as Non-Executive Non-Independent Director via postal ballot. The ordinary resolution passed with 97.07% of votes in favour.
HDFC Bank Annual General Meeting
HDFC Bank's postal ballot passed the appointment of Anup Bagchi as Managing Director and CEO. Approval was deemed on 6 November 2026 with 98.646% votes in favour.
Britannia Industries Annual General Meeting
Britannia shareholders passed the special resolution appointing Sonny Iqbal as Non-Executive Independent Director via postal ballot. Approval was 99.7187% in favour of votes polled.